Chief Scientific Officer
Dr Dahle has more than 20 years of experience in cancer research. He is one of the inventors of Betalutin® and founders of Nordic Nanovector. Dr Dahle has previously held the position of chief executive officer of Nordic Nanovector and leader of the radioimmunotherapy group at Institute for Cancer Research at the Norwegian Radium Hospital. He has published more than 50 papers in the field of cancer and biotechnology. Dr Dahle holds an MSc in biophysics from the Norwegian University for Science and Technology in Trondheim (1995) and a PhD in radiation biology from University of Oslo (2000), and received post-doctoral training in UV-carcinogenesis in the department of radiation biology (2001-2004), the Norwegian Radium Hospital. Dr Dahle has been with the company since incorporation in 2008.